Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-09-07
2011-10-11
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S494000, C514S561000, C514S562000, C514S578000, C514S725000, C424S641000, C424S643000
Reexamination Certificate
active
08034799
ABSTRACT:
Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.
REFERENCES:
patent: 3791988 (1974-02-01), Dieter
patent: 4323558 (1982-04-01), Nelson
patent: 4374829 (1983-02-01), Harris et al.
patent: 4410541 (1983-10-01), Kamimae et al.
patent: 4758583 (1988-07-01), Cerami
patent: 4866090 (1989-09-01), Hoffman et al.
patent: 4952568 (1990-08-01), Sawai et al.
patent: 5077313 (1991-12-01), Lubec
patent: 5128360 (1992-07-01), Cerami et al.
patent: 5246970 (1993-09-01), Williamson et al.
patent: 5366505 (1994-11-01), Farber
patent: 5387109 (1995-02-01), Ishikawa et al.
patent: 5420120 (1995-05-01), Boltralik
patent: 5811446 (1998-09-01), Thomas
patent: 5824049 (1998-10-01), Ragheb et al.
patent: 5852009 (1998-12-01), Cerami et al.
patent: 5854271 (1998-12-01), Thomas et al.
patent: 5906996 (1999-05-01), Murphy
patent: 5972985 (1999-10-01), Thomas et al.
patent: 5980914 (1999-11-01), Gerolymatos
patent: 6147070 (2000-11-01), Facchini
patent: 6309380 (2001-10-01), Larson et al.
patent: 6329414 (2001-12-01), Thomas et al.
patent: 6348465 (2002-02-01), Baker
patent: 6576672 (2003-06-01), Murphy
patent: 6610693 (2003-08-01), Baker
patent: 6821954 (2004-11-01), Reid et al.
patent: 6855511 (2005-02-01), Baker
patent: 6884575 (2005-04-01), Cooper et al.
patent: 6897243 (2005-05-01), Baker et al.
patent: 6951890 (2005-10-01), Cooper et al.
patent: 7582796 (2009-09-01), Jonas
patent: 2002/0034775 (2002-03-01), Baker
patent: 2003/0013772 (2003-01-01), Murphy et al.
patent: 2003/0045506 (2003-03-01), Baker
patent: 2003/0050434 (2003-03-01), Cooper
patent: 2003/0055003 (2003-03-01), Bar-Or et al.
patent: 2003/0055113 (2003-03-01), Wang et al.
patent: 2003/0139312 (2003-07-01), Caswell
patent: 2003/0166561 (2003-09-01), Cooper et al.
patent: 2003/0186946 (2003-10-01), Cooper et al.
patent: 2003/0203973 (2003-10-01), Cooper et al.
patent: 2003/0232799 (2003-12-01), Wang et al.
patent: 2004/0019087 (2004-01-01), Ternansky et al.
patent: 2004/0023854 (2004-02-01), Cooper et al.
patent: 2004/0038861 (2004-02-01), Cooper et al.
patent: 2004/0076603 (2004-04-01), Peled et al.
patent: 2004/0142393 (2004-07-01), Cooper et al.
patent: 2004/0259945 (2004-12-01), Brewer et al.
patent: 2005/0002876 (2005-01-01), Yukl et al.
patent: 2005/0009760 (2005-01-01), Wang et al.
patent: 2005/0031651 (2005-02-01), Gervais et al.
patent: 2005/0047998 (2005-03-01), Cooper et al.
patent: 2005/0074756 (2005-04-01), Cooper et al.
patent: 2005/0085555 (2005-04-01), Murphy et al.
patent: 2005/0159364 (2005-07-01), Cooper et al.
patent: 2005/0159489 (2005-07-01), Baker et al.
patent: 2006/0100278 (2006-05-01), Cooper
patent: 30918/89 (1989-09-01), None
patent: 3217071 (1983-11-01), None
patent: 0 426 066 (1991-05-01), None
patent: 0 576 838 (1994-01-01), None
patent: 1234585 (2002-08-01), None
patent: 2192789 (1988-01-01), None
patent: 2192790 (1988-01-01), None
patent: 7118148 (1995-05-01), None
patent: 2000204037 (2000-07-01), None
patent: P.202419 (1979-12-01), None
patent: WO 8201804 (1982-05-01), None
patent: 85/04169 (1985-09-01), None
patent: WO 87-05505 (1987-09-01), None
patent: WO 95/11690 (1995-05-01), None
patent: 95/17900 (1995-07-01), None
patent: 96/12483 (1996-05-01), None
patent: WO 9840071 (1998-09-01), None
patent: WO 99/39712 (1999-08-01), None
patent: WO 9945907 (1999-09-01), None
patent: 00-18392 (2000-04-01), None
patent: 00/18891 (2000-04-01), None
patent: WO0078805 (2000-12-01), None
patent: 02/43722 (2002-06-01), None
patent: WO02079785 (2002-10-01), None
patent: PCT/US03/02732 (2003-01-01), None
patent: WO03045424 (2003-06-01), None
patent: WO 03/057719 (2003-07-01), None
patent: WO03062275 (2003-07-01), None
patent: WO03063880 (2003-08-01), None
patent: 03/075910 (2003-09-01), None
patent: 03/077901 (2003-09-01), None
patent: WO03074559 (2003-09-01), None
patent: WO 03082259 (2003-10-01), None
patent: WO 03/093311 (2003-11-01), None
patent: WO03093311 (2003-11-01), None
patent: 03/099223 (2003-12-01), None
patent: WO2004012760 (2004-02-01), None
patent: WO2004012761 (2004-02-01), None
patent: 2004/017957 (2004-03-01), None
patent: WO 2004/017957 (2004-03-01), None
patent: WO2004017956 (2004-03-01), None
patent: WO2004056861 (2004-07-01), None
patent: WO2004065614 (2004-08-01), None
patent: WO2004083215 (2004-09-01), None
patent: WO2004087160 (2004-10-01), None
patent: WO2005040205 (2005-05-01), None
patent: WO2005058294 (2005-06-01), None
patent: WO 2006/027705 (2006-03-01), None
patent: WO 2006/068516 (2006-06-01), None
Encyclopedia of Toxicology, vol. 1, Philip Wexler, ed. Published 1998 by Academic Press (San Diego) pp. 376-378.
Pasterkamp & Falk, “Atherosclerotic Plaque Rupture: an Overview”, J. Clin. Basic Cardiol. 3:81-86 (2000).
Allen et al., “Tetramine Cupruretic Agents: A Comparison in Dogs”, Am J Vet Res, vol. 48, No. 1 Jan. 1987.
American Diabetes Association, “Economic Consequences of Diabetes Mellitus in the U.s. in 1997”, Diabetes Care, vol. 21, No. 2, Feb. 1998.
Appelbaum et al., “The Protective Role of Neocuproine Against Cardiac Damage in Isolated Perfused Rat Hearts”, Free Radical Biology & Medicine, vol. 8, pp. 133-143, 1990; Pergamon Press USA.
Baynes, “Role of Oxidative Stress in Diabetic Complications a New Perspective on an Old Paradigm”, Diabetes, vol. 48, Jan. 1999.
Berenshtein et al., “Roles of Ferritin and Iron in Ischemic Preconditions of the Heart”, Molecular and Cellular Biochemistry, 234/235: 283-292, 2002; Kluwer Academic Publishers, Netherlands.
Borthwick et al., “A Comparison of Cupruretic Responses to Various Tetramines and D-Penicillamine”, J Lab Clin Med 95:575, 1980.
Bryszewska et al., “Oxidative Processes in Red Blood Cells from Normal and Diabetic Individuals”, Biochemistry and Molecular Biology International, vol. 37, No. 2, 345-354, Oct. 1995.
Cameron et al., “Ciliary Neuronotrophic Factor Improves Nerve Conduction and Regeneration in Experimental Diabetes”, Diabetologia 38, (Suppl. 1):A233 (Abstract).
Cameron et al., “Neurovascular Dysfunction in Diabetic Rats”, J. Clin. Invest., 1995 96:1159-1163.
Chaturvedi, et al., “Effect of Lisinopril on Progression of Retinopathy in Normotensive People with Type 1 Diabetes”, The Lancet, vol. 351, Jan. 3, 1998.
Cohen, et al., “The Effect of Copper Chelating Drugs on Liver Iron Mobilization on the Adult Rat”, Biochemical and Biophysical Re Communication, vol. 113, No. 1, May 31, 1983, 127-135.
Dahlman et al., “Long-Term Treatment of Wilson's Disease with Triethylene Teramine Dihydrochloride (Trientine)”, O/Med., 1995: 88:609-616.
Deckert et al., “Prognosis of Diabetics with Diabetes Onset6 before the Age of Thirtyone”
Baker John R.
Cooper Garth J. S.
Duane Morris LLP
Henley, III Raymond J
Philera New Zealand Limited
LandOfFree
Preventing and/or treating cardiovascular disease and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preventing and/or treating cardiovascular disease and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventing and/or treating cardiovascular disease and/or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4262706